Research Summaries 2 - Oncology Matrix

Chest Wall Perforator Flaps are Safe and Can Decrease Mastectomy Rates in Breast Cancer Surgery: Multicenter Cohort Study

In preinvasive and invasive breast cancer, breast-conserving surgery (BCS) has demonstrated similar survival outcomes to mastectomy, in addition to improvements in outcomes such

Acalabrutinib-based Regimens in Frontline or Relapsed/Refractory Higher-risk CLL: Pooled Analysis of 5 Clinical Trials

Research Summary Patients with chronic lymphocytic leukemia (CLL) and higher-risk genomic features, such as unmutated immunoglobulin heavy chain variable (IGHV), del(17p) and/or TP53

Durvalumab After Chemoradiotherapy for Locoregional Recurrence of Completely Resected Non-small Cell Lung Cancer (NEJ056)

Research Summary Up to 35 percent of patients with completely resected non-small cell lung cancer (NSCLC) experience locoregional recurrence (LR), and many of

A Preoperative Window-of-opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-positive, HER2-negative Early Breast Cancer: Results from EMBER-2 Study

Preoperative window-of-opportunity studies can provide key information on molecular drug response, pharmacodynamic (PD) effects, and downstream effects of medications, such as endocrine therapy

Integrating the Melanoma 31-gene Expression Profile Test with Clinical and Pathologic Features Can Provide Personalized Precision Estimates for Sentinel Lymph Node Positivity: An Independent Performance Cohort

Research Summary: Sentinel lymph node biopsy (SLNB) is recommended for patients with melanoma and a likelihood of SLN positivity above 10 percent, and

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination with Targeted Therapy in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

Endocrine therapy (ET) is the standard of care for patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC), but efficacy and patient experiences

Intracranial Outcomes of De Novo Brain Metastases Treated with Osimertinib Alone in Patients with Newly Diagnosed EGFR-mutant NSCLC

Research Summary Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations have a notably increased incidence of brain

Detailed Safety Profile of Acalabrutinib vs. Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia in the ELEVATE-RR Trial

Research Summary Bruton tyrosine kinase (BTK) inhibitors are often used to treat chronic lymphocytic leukemia (CLL). Ibrutinib is a covalent BTK inhibitor associated

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Research Summary Acalabrutinib, a next-generation covalent Bruton tyrosine kinase (BTK) inhibitor, has shown efficacy and tolerability in the treatment of chronic lymphocytic leukemia